Adagene (ADAG) Competitors $1.91 -0.03 (-1.55%) Closing price 07/11/2025 03:51 PM EasternExtended Trading$1.88 -0.03 (-1.52%) As of 07/11/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAG vs. ARCT, MBX, CMPX, TERN, HUMA, PRTA, HRTX, AMRN, PRME, and SNDLShould you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Arcturus Therapeutics (ARCT), MBX Biosciences (MBX), Compass Therapeutics (CMPX), Terns Pharmaceuticals (TERN), Humacyte (HUMA), Prothena (PRTA), Heron Therapeutics (HRTX), Amarin (AMRN), Prime Medicine (PRME), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry. Adagene vs. Its Competitors Arcturus Therapeutics MBX Biosciences Compass Therapeutics Terns Pharmaceuticals Humacyte Prothena Heron Therapeutics Amarin Prime Medicine SNDL Adagene (NASDAQ:ADAG) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment. Which has more volatility and risk, ADAG or ARCT? Adagene has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Which has higher earnings and valuation, ADAG or ARCT? Adagene has higher earnings, but lower revenue than Arcturus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdagene$100K899.80-$33.42MN/AN/AArcturus Therapeutics$152.31M2.45-$80.94M-$2.53-5.45 Does the media favor ADAG or ARCT? In the previous week, Adagene had 3 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 4 mentions for Adagene and 1 mentions for Arcturus Therapeutics. Adagene's average media sentiment score of 0.79 beat Arcturus Therapeutics' score of 0.14 indicating that Adagene is being referred to more favorably in the media. Company Overall Sentiment Adagene Positive Arcturus Therapeutics Neutral Do analysts prefer ADAG or ARCT? Adagene presently has a consensus target price of $8.00, indicating a potential upside of 318.85%. Arcturus Therapeutics has a consensus target price of $54.00, indicating a potential upside of 291.87%. Given Adagene's higher possible upside, research analysts clearly believe Adagene is more favorable than Arcturus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Do institutionals & insiders have more ownership in ADAG or ARCT? 9.5% of Adagene shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 21.2% of Adagene shares are owned by insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is ADAG or ARCT more profitable? Adagene has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -47.47%. Adagene's return on equity of 0.00% beat Arcturus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AdageneN/A N/A N/A Arcturus Therapeutics -47.47%-27.41%-19.01% SummaryAdagene beats Arcturus Therapeutics on 9 of the 15 factors compared between the two stocks. Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAG vs. The Competition Export to ExcelMetricAdageneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.98M$2.94B$5.55B$9.11BDividend YieldN/A2.42%5.07%4.01%P/E RatioN/A20.7128.2120.26Price / Sales899.80292.82432.0099.74Price / CashN/A42.1137.1257.67Price / Book1.687.638.045.49Net Income-$33.42M-$55.05M$3.19B$250.45M7 Day Performance1.33%8.43%3.63%4.79%1 Month Performance-2.55%5.42%4.06%7.68%1 Year Performance-30.80%2.03%30.02%16.44% Adagene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAGAdagene2.5996 of 5 stars$1.91-1.5%$8.00+318.8%-29.5%$89.98M$100K0.00260ARCTArcturus Therapeutics1.7393 of 5 stars$13.01-2.4%$53.50+311.2%-42.0%$361.52M$152.31M-5.14180Gap DownMBXMBX Biosciences2.6032 of 5 stars$11.41+6.1%$37.50+228.7%N/A$359.31MN/A0.0036Positive NewsCMPXCompass Therapeutics3.0158 of 5 stars$2.60+1.6%$13.13+404.8%+159.6%$354M$850K-6.3420News CoveragePositive NewsTERNTerns Pharmaceuticals3.9122 of 5 stars$3.73-2.6%$15.63+318.9%-41.2%$334.50MN/A-3.4240HUMAHumacyte2.205 of 5 stars$2.09-1.4%$11.71+460.5%-64.2%$328.85M$1.57M-3.03150Analyst ForecastPRTAProthena3.6255 of 5 stars$6.07-0.2%$31.50+418.9%-71.4%$327.27M$135.16M-2.92130HRTXHeron Therapeutics3.6811 of 5 stars$2.07-3.3%$5.00+141.5%-34.1%$326.49M$144.29M-34.50300AMRNAmarin0.441 of 5 stars$16.22+3.2%$12.00-26.0%+13.5%$325.31M$228.61M-4.46360Positive NewsHigh Trading VolumePRMEPrime Medicine3.905 of 5 stars$2.47+2.1%$10.08+308.2%-27.5%$324.30M$3.85M-1.20234High Trading VolumeSNDLSNDL3.034 of 5 stars$1.21-1.6%$3.63+199.6%-36.2%$323.21M$671.81M-4.172,516News Coverage Related Companies and Tools Related Companies ARCT Competitors MBX Competitors CMPX Competitors TERN Competitors HUMA Competitors PRTA Competitors HRTX Competitors AMRN Competitors PRME Competitors SNDL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAG) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
